Nektar Therapeutics (NASDAQ:NKTR) SVP Ivan P. Gergel sold 54,920 shares of Nektar Therapeutics stock in a transaction on Tuesday, July 18th. The stock was sold at an average price of $21.10, for a total value of $1,158,812.00. Following the sale, the senior vice president now directly owns 98,492 shares of the company’s stock, valued at $2,078,181.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Nektar Therapeutics (NASDAQ NKTR) traded up 2.35% on Thursday, reaching $22.17. The company’s stock had a trading volume of 1,879,344 shares. Nektar Therapeutics has a 52-week low of $11.41 and a 52-week high of $24.88. The stock’s market cap is $3.44 billion. The firm’s 50-day moving average price is $19.58 and its 200-day moving average price is $17.44.

Nektar Therapeutics (NASDAQ:NKTR) last issued its earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.42) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.40) by $0.02. The firm had revenue of $24.73 million during the quarter, compared to analyst estimates of $29.43 million. Nektar Therapeutics had a negative net margin of 150.74% and a negative return on equity of 3,072.86%. The business’s quarterly revenue was down 58.0% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.14) earnings per share. On average, equities analysts expect that Nektar Therapeutics will post ($1.17) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Nektar Therapeutics (NASDAQ:NKTR) SVP Sells $1,158,812.00 in Stock” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/07/20/nektar-therapeutics-nasdaqnktr-svp-sells-1158812-00-in-stock.html.

A number of brokerages recently commented on NKTR. Zacks Investment Research raised Nektar Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, March 27th. William Blair reaffirmed an “outperform” rating on shares of Nektar Therapeutics in a research note on Tuesday. Aegis boosted their target price on Nektar Therapeutics from $24.00 to $27.00 and gave the company a “buy” rating in a research note on Thursday, April 6th. ValuEngine raised Nektar Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Finally, BidaskClub raised Nektar Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, June 27th. Two analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $26.29.

Hedge funds have recently modified their holdings of the stock. Flinton Capital Management LLC increased its stake in shares of Nektar Therapeutics by 11.1% in the first quarter. Flinton Capital Management LLC now owns 4,480 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 448 shares in the last quarter. State of Alaska Department of Revenue increased its stake in shares of Nektar Therapeutics by 2.8% in the first quarter. State of Alaska Department of Revenue now owns 17,050 shares of the biopharmaceutical company’s stock valued at $400,000 after buying an additional 460 shares in the last quarter. Louisiana State Employees Retirement System increased its stake in shares of Nektar Therapeutics by 0.8% in the second quarter. Louisiana State Employees Retirement System now owns 63,200 shares of the biopharmaceutical company’s stock valued at $1,236,000 after buying an additional 500 shares in the last quarter. LS Investment Advisors LLC increased its stake in shares of Nektar Therapeutics by 8.8% in the second quarter. LS Investment Advisors LLC now owns 6,594 shares of the biopharmaceutical company’s stock valued at $129,000 after buying an additional 535 shares in the last quarter. Finally, Municipal Employees Retirement System of Michigan increased its stake in shares of Nektar Therapeutics by 1.7% in the first quarter. Municipal Employees Retirement System of Michigan now owns 34,920 shares of the biopharmaceutical company’s stock valued at $820,000 after buying an additional 570 shares in the last quarter. Institutional investors own 93.85% of the company’s stock.

Nektar Therapeutics Company Profile

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Insider Buying and Selling by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.